GHK-Cu vs AHK-Cu: Copper Tripeptides Compared

GHK-Cu and AHK-Cu sit side by side in almost every research-peptide catalog, their names differ by a single letter, and they are routinely described as if they were near-equivalents — a well-documented peptide and its close cousin. The chemistry half of that description is accurate: the two molecules really do differ by one amino acid. The evidence half is not. GHK-Cu has been studied since the 1970s, in cell cultures, animal wound models, gene-expression datasets and human cosmetic trials. AHK-Cu's entire primary literature consists of one in vitro and ex vivo study from 2007. This comparison lays out both records side by side, because for a researcher choosing between them, the distance between those two evidence bases is the most important fact on the page.

One Residue Apart

• GHK-Cu: glycyl–histidyl–lysine complexed with copper(II). The peptide GHK is a tripeptide of approximately 340.4 Da, first isolated from human plasma in the 1970s by Loren Pickart and characterized as a naturally occurring copper-binding peptide whose plasma levels decline with age.
• AHK-Cu: alanyl–histidyl–lysine complexed with copper(II), approximately 354.4 Da as the peptide. AHK is a synthetic analog: the N-terminal glycine of GHK is replaced by alanine, which adds a single methyl group. AHK has no known natural source and no established physiological role.

In both molecules the copper ion is held by the same core apparatus — the histidine imidazole ring, the N-terminal amino group and the intervening amide nitrogen — forming a 1:1 peptide–copper chelate, and in both cases the specified research material is the complex, not the free peptide. GHK's copper binding has been quantified extensively and is exceptionally tight for a peptide of its size, which underlies the hypothesis, developed across Pickart's work, that GHK functions in part as a copper-delivery and copper-buffering molecule. AHK-Cu's binding has been characterized far less; it is generally assumed to chelate copper in the same geometry, but the assumption is an extrapolation from the shared His-Lys core, not a measured equivalence. A one-methyl-group difference sounds trivial, and in peptide pharmacology it routinely is not: N-terminal identity shapes receptor and enzyme recognition, protease susceptibility and transport. The literature treats the two as distinct compounds, and so should buyers.

Why the Two Are So Often Confused

Three forces blur the line in the marketplace. First, naming: cosmetic ingredient lists know GHK-Cu as Copper Tripeptide-1, and AHK-Cu circulates in hair-care formulations under similar "copper peptide" labeling, so the two appear interchangeable on product pages even though the ingredient names refer to different molecules. Second, portfolio logic: suppliers stock both, describe both with the vocabulary of the copper-peptide category, and rarely distinguish which findings belong to which compound. Third, blends: widely sold research blends in this category are built on GHK-Cu, and their descriptions reinforce the impression that "copper tripeptide" is a single interchangeable ingredient. It is not — it is a family name covering (at least) two distinct chelates with distinct records, and any citation attached to the family should be traced to the molecule actually studied.

The GHK-Cu Record: Five Decades, Several Evidence Layers

Matrix biology in culture and in wounds

The foundational experimental work came from François-Xavier Maquart's group in Reims. In 1988 they reported in FEBS Letters that the GHK–copper complex stimulated collagen synthesis in fibroblast cultures. The program continued into living tissue: a 1992 Life Sciences study examined glycosaminoglycan synthesis in rat experimental wounds, and in 1993 the group reported in the Journal of Clinical Investigation that GHK-Cu increased connective tissue accumulation in rat wound chambers, with effects on collagen and glycosaminoglycan content. These are the studies most often cited for GHK-Cu's "skin" reputation, and it is worth being precise about what they are: cell-culture and rodent wound-model data showing the complex is biologically active on extracellular-matrix pathways — not demonstrations of cosmetic or clinical outcomes.

The copper-delivery hypothesis

A recurring interpretive thread in the GHK-Cu literature is that the peptide's tight, specific copper binding is not incidental to its biology but central to it. On this account, GHK functions as a copper chaperone in miniature — binding Cu2+ in plasma and delivering or redistributing it at sites of tissue remodeling, where several copper-dependent enzymes involved in matrix formation and antioxidant defense operate. Pickart's reviews develop this hypothesis at length, connecting the peptide's decline in plasma with age to its research profile. Like the gene-expression breadth, the copper-delivery model is best classified as a well-articulated, partially supported framework rather than a settled mechanism — but it is a framework that exists only for GHK-Cu. Whether AHK-Cu, with its altered N-terminus adjacent to the binding site, handles copper identically in biological media is an open experimental question, and one more reason the two compounds' records cannot simply be merged.

Gene-expression breadth

A second, distinct layer of the record is genomic. Using gene-expression datasets, Pickart and Margolina reported that GHK modulates the expression of a remarkably large number of human genes — thousands, across pathways involved in tissue remodeling, antioxidant defense, inflammation and nervous-system function — work summarized in their 2015 review in BioMed Research International and their 2018 review in the International Journal of Molecular Sciences. This breadth is genuinely unusual for a tripeptide and is the main reason GHK-Cu remains an active research subject. It is also double-edged: a molecule reported to touch that many pathways is a systems-biology probe, and broad gene modulation in expression datasets is not, by itself, evidence of a specific benefit in a specific tissue.

Human data

GHK-Cu also has something AHK-Cu entirely lacks: human exposure data. Copper-peptide preparations containing GHK-Cu have been tested in controlled cosmetic studies of skin appearance parameters, and the peptide has a long history of topical use in commercial formulations. That record is cosmetic in scope — appearance endpoints, not disease treatment — but it means GHK-Cu's local tolerability and behavior on human skin have at least been examined directly.

The AHK-Cu Record: One Study, Carefully Read

Against that accumulation stands a single paper. In 2007, Pyo and colleagues reported in the Archives of Pharmacal Research on the effect of the alanine variant's copper complex on human hair growth in vitro. Working with cultured human hair follicles and dermal papilla cells, they found that AHK-Cu promoted follicle elongation ex vivo and stimulated dermal papilla cell proliferation, at concentrations in the picomolar-to-nanomolar range. The mechanistic markers moved in a coherent direction: the Bcl-2/Bax ratio rose, suggesting a shift away from apoptosis in the papilla cells, while cleaved caspase-3 and cleaved PARP — execution markers of programmed cell death — fell.

It is a well-constructed study of its type, and its type is the point. It is one laboratory's in vitro and organ-culture result. There are no published AHK-Cu animal wound studies, no angiogenesis studies, no gene-expression datasets, and no human trials of any kind. When catalog copy attributes collagen, wound-healing or gene-modulation findings to "copper tripeptides" in a way that sweeps AHK-Cu along, it is borrowing GHK-Cu's record wholesale — the Maquart experiments, the wound chambers, the genomic analyses were all performed with the glycine peptide. None of them tested AHK-Cu.

Two further gaps deserve naming. The 2007 study has not, in the published record, been followed by an independent replication or by an in vivo extension from any group — nearly two decades of silence after a positive, commercially interesting result is itself information about the state of the field. And AHK-Cu lacks even the basic characterization layer GHK-Cu accumulated early: no published plasma or tissue occurrence data (unsurprising for a synthetic molecule), no systematic copper-binding quantification, and no stability or degradation profile in the open literature. A researcher designing AHK-Cu experiments is therefore working with less scaffolding at every level — not only fewer efficacy-adjacent results, but fewer of the routine chemical reference points that make results interpretable.

Side-by-Side Summary of the Differences

• Identity: GHK-Cu = Gly-His-Lys·Cu2+, an endogenous human plasma peptide. AHK-Cu = Ala-His-Lys·Cu2+, a synthetic analog with no known natural occurrence.
• Primary literature: GHK-Cu — dozens of studies spanning five decades. AHK-Cu — one primary study (Pyo et al., 2007).
• Model systems covered: GHK-Cu — fibroblast cultures, rodent wound models, gene-expression analyses, human cosmetic studies. AHK-Cu — human hair follicle organ culture and dermal papilla cells only.
• Mechanistic themes: GHK-Cu — extracellular-matrix synthesis, copper handling, broad gene modulation. AHK-Cu — dermal papilla cell survival signaling (Bcl-2/Bax, caspase-3, PARP) in a follicle context.
• Research niche today: GHK-Cu — skin matrix biology, wound-healing models, copper-peptide chemistry. AHK-Cu — hair-follicle and dermal papilla research, where its one direct study actually lives.

Choosing Between Them in the Laboratory

The honest selection logic follows from the records rather than from the names. A researcher modeling skin matrix biology or copper-peptide chemistry has every reason to work with GHK-Cu: the comparator literature exists, the expected behaviors in fibroblast systems are documented, and deviations from published results are interpretable. A researcher working specifically on hair-follicle or dermal papilla models faces a more interesting choice — AHK-Cu is the compound with the direct follicle data, thin as it is, while GHK-Cu offers a deeper surrounding literature that does not include the same follicle experiments. What neither record supports is treating the two as interchangeable reagents, or citing one's data in a protocol built on the other.

Analytical Checks: The Copper Is Part of the Specification

Both compounds are metallopeptides, and that creates a verification requirement ordinary peptides do not have: the certificate of analysis must establish not just the peptide but the complex. Three checks matter. First, purity by HPLC, the standard chromatographic measure. Second, identity by mass spectrometry against the expected mass of the complex — the peptide mass plus copper, less the two protons displaced on binding (for AHK-Cu, an expected complex mass of approximately 417 Da was the figure used when NUPEPS PEPTIDES published its AHK-Cu guide; the same arithmetic applies to GHK-Cu at approximately 402 Da). Third, copper content itself: material that has lost its copper in synthesis or storage, or that carries free copper salt as a contaminant, is not the specified chelate even if the peptide portion is pure — and a peptide-only purity percentage will not reveal either failure. Net peptide content, the third standard check, completes the picture by stating how much of the lyophilized mass is the specified complex at all.

The Bottom Line

GHK-Cu and AHK-Cu are chemical near-neighbors and evidential opposites. One is an endogenous peptide with fifty years of accumulated, multi-layer research — real, but concentrated in preclinical models and cosmetic endpoints. The other is a rational synthetic variant whose reputation in the marketplace is almost entirely inherited from its cousin, and whose own file contains a single, genuinely interesting follicle study. NUPEPS PEPTIDES supplies both strictly as laboratory research materials. A careful researcher's takeaway is simple: choose by the experiment, cite by the molecule, and never let a shared surname — or a single methyl group — do the evidentiary work.